As of November 6, 2026, IN8BIO, Inc. is a publicly traded company (Nasdaq: INAB); its largest reported holder is Lytton Laurence W, with 9.99% on Schedule 13G/A of August 13, 2026, then Alyeska (9.9%) (Schedule 13G/A, August 13, 2026).
Is this your company?
About to sign with, pay or invest in IN8BIO, Inc.? See the free Snapshot first.
Free to see. No signup.
Is IN8BIO, Inc. a real, registered company?
- In8bio, Inc. files with the SEC under CIK 1740279 (its SEC filings).
- Its shares are listed under the ticker INAB on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under IN8BIO, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Lytton Laurence W (filed 2026-08-13).
Who are IN8BIO, Inc.'s owners and officers?
IN8BIO, Inc.: incorporated in Delaware; business address in New York, New York; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-13).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-12-30)
- : Executive Officer (Form D, 2025-12-30)
- : Director (Form D, 2025-12-30)
- : Director (Form D, 2025-12-30)
- : Director (Form D, 2025-12-30)
- : Director (Form D, 2025-12-30)
- : Director (Form D, 2025-12-30)
- : Director (Form D, 2025-12-30)
- : Executive Officer (Form D, 2025-12-30)
- : Executive Officer (Form D, 2025-12-30)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Lytton Laurence W | 9.99% |
| Schedule 13D/A, 2026-05-29 | Emily Fairbairn | 2.2% |
| Schedule 13G, 2026-03-02 | Lytton Laurence W | 9.99% |
| Schedule 13G, 2026-02-17 | Alyeska Investment Group, L.P. | 9.9% |
| Schedule 13G, 2026-01-29 | Franklin Resources, Inc. | 9.4% |
| Schedule 13D, 2026-01-02 | Emily Fairbairn | 7.5% |
| Schedule 13G, 2025-12-30 | 683 Capital Management, LLC | 7.86% |
| Schedule 13D/A, 2025-12-29 | Bios Fund Ii, LP | 4% |
| Schedule 13G, 2025-12-22 | Stonepine Capital Management, LLC | 9.9% |
| Schedule 13G/A, 2025-08-14 | Alyeska Investment Group, L.P. | 2.58% |
| Schedule 13G/A, 2025-08-13 | Transcend Partners Opportunity Fund LLC | 2.6% |
| Schedule 13G/A, 2025-08-13 | William Tai-Wei Ho | 3.7% |
Questions about who owns IN8BIO, Inc.
Who owns IN8BIO, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of IN8BIO, Inc.: Lytton Laurence W (9.99%, Schedule 13G/A, filed 2026-08-13), Alyeska Investment Group, L.P. (9.9%, Schedule 13G, filed 2026-02-17), Stonepine Capital Management, LLC (9.9%, Schedule 13G, filed 2025-12-22), Franklin Resources, Inc. (9.4%, Schedule 13G, filed 2026-01-29) and 683 Capital Management, LLC (7.86%, Schedule 13G, filed 2025-12-30).
Who are the largest shareholders of IN8BIO, Inc.?
By the share each holder's latest filing reports, the largest holders of IN8BIO, Inc. on this page are Lytton Laurence W (9.99%), Alyeska Investment Group, L.P. (9.9%) and Stonepine Capital Management, LLC (9.9%).
When did Lytton Laurence W buy into IN8BIO, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lytton Laurence W on this page is the Schedule 13G, filed 2026-03-02, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-13, reports 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on IN8BIO, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on IN8BIO, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on IN8BIO, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own IN8BIO, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 8,600,001 shares (79.6% of shares outstanding), held indirectly through By Bios Fund II, LP and 2 others, on a joint filing (Form 4, 2025-05-07).
- Bios Equity COF, LP, a 10% owner: 8,600,001 shares (79.6% of shares outstanding), held indirectly through By Bios Fund II, LP and 2 others, on a joint filing (Form 4, 2025-05-07).
- BIOS Advisors GP, LLC, a 10% owner: 8,600,001 shares (79.6% of shares outstanding), held indirectly through By Bios Fund II, LP and 2 others, on a joint filing (Form 4, 2025-05-07).
- BIOS Fund II NT, LP, a 10% owner: 8,600,001 shares (79.6% of shares outstanding), held indirectly through By Bios Fund II, LP and 2 others, on a joint filing (Form 4, 2025-05-07).
- BIOS Fund II QP, LP, a 10% owner: 8,600,001 shares (79.6% of shares outstanding), held indirectly through By Bios Fund II, LP and 2 others, on a joint filing (Form 4, 2025-05-07).
Shares outstanding: 10,808,292 as of 2026-11-02, from the company's latest SEC cover page.
How much has IN8BIO, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-12-30 | $20.12M | $40.24M |
| Form D, 2024-10-15 | $12.38M | $12.38M |
| Form D, 2023-12-28 | $14.43M | $14.43M |
Keep reading
More on IN8BIO, Inc. and the records around it.
IN8BIO, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Dec 2025
Companies that share a holder
- 683 Capital Management, LLC also filed stake reports on 10 other companies: Perceptive Capital Solutions Corp (Aug 2026), Gossamer Bio, Inc. (Jun 2026), FRACTYL HEALTH, INC. (May 2026)
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), Edesa Biotech, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- LYTTON LAURENCE W also filed stake reports on 28 other companies: Retension Pharmaceuticals, Inc. (Oct 2026), Rank One Computing Corp (Aug 2026), MDxHealth SA (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/in8bio